Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: An 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial

Clinical Therapeutics

Volumn 31, Issue 5, 2009, Pages 988-998

  Kim, Sang Hyun ^a,b   Chung, Woo Young ^a,b   Zo, Joo Hee ^a,b   Kim, Myung A ^a,b   Chang, Hyuk Jae ^b,c   Cho, Young Seok ^b,c   Youn, Tae Jin ^b,c   Chae, In Ho ^b,c   Choi, Dong Joo ^b,c   Gwak, Jae Jin ^b,d   Lee, Hae Young ^b,d   Park, Jin Sik ^b,d   Kang, Hyun Jae ^b,d   Kim, Young Jin ^b,d   Kim, Hyo Soo ^b,d  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

blood pressure; hypertension; ramipril

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GENERIC DRUG; HYDROCHLOROTHIAZIDE; RAMIPRIL; RAMIPRIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MARKETING; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; ESSENTIAL HYPERTENSION; EXERCISE; FATIGUE; FEMALE; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; KOREA; LOW BACK PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL EDEMA; PRURITUS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; REST; RHINITIS; SIDE EFFECT; SITTING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY FREQUENCY; VERTIGO; WEAKNESS; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KOREA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RAMIPRIL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 67149087224     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.05.020     Document Type: Article

References (16)

1. Lewington S., Clarke R., Qizilbash N., et al., the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003;361:1060]. Lancet 360 (2002) 1903-1913
2. McCarron D., and the Ramipril Multicenter Study Group. 24-Hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects. Clin Cardiol 14 (1991) 737-742
3. Swedberg K., Kjekshus J., and Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 20 (1999) 136-139
4. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
5. Lenox-Smith A.J., Street R.B., and Kendall F.D. Comparison of ramipril against atenolol in controlling mild-to-moderate hypertension. J Cardiovasc Pharmacol 18 Suppl 2 (1991) S150-S152
6. Schnaper H.W. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 18 Suppl 2 (1991) S128-S130
7. Erhard W., Lindner U., Krall H., et al. Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: A retrospective analysis. J Cardiovasc Pharmacol 18 Suppl 2 (1991) S160-S164
8. Schwartz S.L., Hanson C., Lucas C., et al. Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension. Clin Ther 15 (1993) 79-87
9. Gianni M., Bosch J., Pogue J., et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 28 (2007) 1382-1388
10. Ahimastos A.A., Dart A.M., Lawler A., et al. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens 26 (2008) 1037-1042
11. Ahimastos A.A., Lawler A., Reid C.M., et al. Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease: A randomized trial. Ann Intern Med 144 (2006) 660-664
12. Mitrovic V., Klein H.H., Krekel N., et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 94 (2005) 336-342
13. Ghiadoni L., Versari D., Magagna A., et al. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 25 (2007) 361-366
14. European Medicines Agency. ICH Topic E 6 (R1). Guideline for good clinical practice. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed April 16, 2009
15. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm Accessed April 16, 2009
16. Freedman D., Pisani R., and Purves R. Statistics. 4th ed. (2007), WW Norton & Company, New York, NY